Clinical Trial Results

Clinical Trial Results

No drugs receive FDA approval for use in CLL/SLL or come to market without being first evaluated for safety, efficacy, dosage, and many other factors in clinical trials.

For over a decade, CLL Society’s founders and staff have reported from all the major hematology conferences to bring CLL/SLL patients and caregivers the most up-to-date clinical trial data.

As clinical trials are studies that reveal what is being learned over time, CLL Society urges patients and caregivers to diligently follow CLL Society’s year-round reporting of clinical trial data from all of the major blood cancer conferences.

The published results of many of the trials that can help us better manage our CLL/SLL treatment options will be posted here. Additional helpful information might be found on other areas of the website under specific trial subjects, such as COVID-19, Richter’s Transformation, Relapsed/Refractory CLL/SLL, or trial name, etc.

Action Items for Clinical Trial Results

Sign up for CLL Society: This Week.

CLL Society’s weekly newsletter CLL Society: This Week will be delivered to your inbox every Tuesday morning as CLL Society publishes articles and video interviews reporting the latest clinical trial data readouts year round.

Search clinical trials.

Use CLL Society’s website search bar for further assistance in cross-referencing information about clinical trials you are interested in.

Sign up for CLL Society: This Week.

CLL Society’s weekly newsletter CLL Society: This Week will be delivered to your inbox every Tuesday morning as CLL Society publishes articles and video interviews reporting the latest clinical trial data readouts year round.

Search clinical trials.

Use CLL Society’s website search bar for further assistance in cross-referencing information about clinical trials you are interested in.

FEATURE

ASH 2021: BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Dr. Jeff Sharman and colleagues presented this research at the American Society for Hematology annual meeting held December 2021 (ASH 2021).

Background:

Bruton tyrosine kinase (BTK) inhibitors revolutionized the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). Currently available BTK inhibitors, such as ibrutinib and acalabrutinib, work by forming irreversible (covalent) bonds with BTK that inhibit its activity. However, some patients develop resistance mutations such as the C481S mutation at the binding site, which prevents irreversible BTK inhibitors from binding to BTK and render the drug ineffective, resulting in relapse. Read More.

ADDITIONAL READING

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a
This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients without the high-risk mutation,17p deletion